"Bile Ducts, Intrahepatic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
| Descriptor ID |
D001653
|
| MeSH Number(s) |
A03.159.183.158 A03.620.150
|
| Concept/Terms |
Bile Ducts, Intrahepatic- Bile Ducts, Intrahepatic
- Bile Duct, Intrahepatic
- Duct, Intrahepatic Bile
- Ducts, Intrahepatic Bile
- Intrahepatic Bile Duct
- Intrahepatic Bile Ducts
|
Below are MeSH descriptors whose meaning is more general than "Bile Ducts, Intrahepatic".
Below are MeSH descriptors whose meaning is more specific than "Bile Ducts, Intrahepatic".
This graph shows the total number of publications written about "Bile Ducts, Intrahepatic" by people in this website by year, and whether "Bile Ducts, Intrahepatic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 3 | 5 | 8 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 4 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 4 | 3 | 7 |
| 2007 | 12 | 2 | 14 |
| 2008 | 7 | 2 | 9 |
| 2009 | 3 | 2 | 5 |
| 2010 | 7 | 2 | 9 |
| 2011 | 9 | 3 | 12 |
| 2012 | 8 | 1 | 9 |
| 2013 | 3 | 1 | 4 |
| 2014 | 4 | 3 | 7 |
| 2015 | 3 | 2 | 5 |
| 2016 | 2 | 0 | 2 |
| 2017 | 5 | 2 | 7 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 18 | 18 |
| 2023 | 1 | 22 | 23 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bile Ducts, Intrahepatic" by people in Profiles.
-
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clin Cancer Res. 2024 Apr 15; 30(8):1466-1477.
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
-
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862.
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 02; 80(2):322-334.
-
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist. 2023 Nov 02; 28(11):928-943.
-
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
-
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma. Ann Surg Oncol. 2023 12; 30(13):7960-7965.
-
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 09 06; 13(9):2012-2031.
-
What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma? Cancer J. 2023 Sep-Oct 01; 29(5):272-278.
-
Imaging Findings in Cirrhotic Liver: Pearls and Pitfalls for Diagnosis of Focal Benign and Malignant Lesions. Radiographics. 2023 09; 43(9):e230043.